 ROCKVILLE, MD, Dec. 07, 2020 GLOBE NEWSWIRE -- MacroGenics, Inc. NASDAQ: MGNX, a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced updated results from a dose expansion study of tebotelimab, an investigational, bispecific PD-1 × LAG-3 DART molecule, in patients with diffuse large B-cell lymphoma DLBCL. The data were presented at the 62nd Annual Meeting of the American Society of Hematology ASH taking place December 5-8, 2020. 